Discovery of plasma biomarkers related to blood-brain barrier dysregulation in Alzheimer's disease
Alzheimer’s disease (AD) is the most common cause of dementia. However, current diagnostic tools are subjective, cost-inefficient, and difficult to administer. Blood-based biomarkers, which are quantitative and non-invasive, have thus been increasingly investigated as potential diagnostic tools. Exp...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project |
| Language: | English |
| Published: |
Nanyang Technological University
2024
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/176360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Alzheimer’s disease (AD) is the most common cause of dementia. However, current diagnostic tools are subjective, cost-inefficient, and difficult to administer. Blood-based biomarkers, which are quantitative and non-invasive, have thus been increasingly investigated as potential diagnostic tools. Exploiting the well-established blood-brain barrier (BBB) dysregulation in AD, this study hypothesized that with BBB dysfunction, brain-synthesised proteins could leak into peripheral circulation for increased detection. Differential abundance analysis was performed on pooled datasets of plasma and brain proteomics, and integration revealed a novel panel of 5 plasma proteins which yielded an AUROC of 0.70 in a separate plasma dataset: APOD, B2M, CFH, CLU and C3. Proteins were confirmed to be associated with AD neuropathology and disassociated with peripheral inflammation and other neurodegenerative diseases. Single-cell transcriptomics revealed an upregulation of 4 of the protein transcripts in AD astrocytes, mediated by 3 transcription factors involved in neuroinflammation that are upregulated in AD: JUNB, CEBPB and ZEB1. CLU was further shown to regulate the downstream expression of neuronal death genes. Interestingly, preliminary evidence implicated the LRP receptor family in brain-to-blood protein leakage in AD. Future research should investigate the regulation of this receptor-mediated transcytosis pathway in AD and validate the biomarker panel in clinical samples. |
|---|